Genomic Instability in Chronic Myeloid Leukemia: Targets for Therapy?
| Autor: | Pratik K. Nagaria, Nidal Muvarak, Feyruz V. Rassool |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Genome instability
Cancer Research medicine.medical_specialty DNA damage DNA repair Philadelphia positive Genomic Instability Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine medicine Humans Molecular Targeted Therapy Gene Hematology business.industry Myeloid leukemia Transformation (genetics) Cell Transformation Neoplastic Oncology Immunology Disease Progression Reactive Oxygen Species business DNA Damage |
| Zdroj: | Current Hematologic Malignancy Reports. 7:94-102 |
| ISSN: | 1558-822X 1558-8211 |
| Popis: | Philadelphia positive (Ph+) chronic myeloid leukemia (CML) is characterized by the occurrence of nonrandom genetic and cytogenetic abnormalities during disease progression. Many of these abnormalities are markers for genes which, when altered, can drive the blastic transformation process. Thus, such genetic alterations may be manifestations of an underlying genomic instability resulting from a compromised DNA damage and repair response, leading to advanced stages of CML and resistance to therapy. This article examines the molecular pathways that may lead to genomic instability in CML and the potential of these pathway constituents to be therapeutic targets. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink